Knee cartilage defect
Conditions
Interventions
Experimental group:PRP treatment
Control group:Subchondral drilling
Sponsors
The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. The patient's gender is not limited, and aged 18-60 years; 2. According to the diagnostic criteria for knee osteoarthritis recommended by the American College of Rheumatology, the X-ray grading standard is graded according to SasaKit, which is in line with grades I-IV; 3. Before the start of the study, the subjects are willing and able to sign the informed consent form approved by the ethics committee; 4. Willing to cooperate closely with the strict postoperative rehabilitation procedures formulated by the doctor; 5. The patient himself is willing to cooperate with the whole treatment process, and is willing to bear the corresponding consequences or related complications after the treatment process, and the corresponding postoperative treatment measures; 6. According to the judgment of the researcher, the subjects can understand the clinical research and can cooperate to complete the whole research process; 7. The subject can read, express and understand the content of the research protocol, and can provide feedback in appropriate language; 8. No history of previous knee surgery.
Exclusion criteria
Exclusion criteria: 1.The patient was unable to provide written consent to participate in the clinical study; 2. The patient was obese with a BMI of 30 kg/m2; 3. The patient had type X or type O legs; 4. A known history of immune system disease resulting in joint and meniscus damage; 5. Kellgren & Lawrence Grade III and above arthritis with extensive damage to the meniscus; 6. With severe cardiac, liver, kidney and lung insufficiency; 7. Pregnant and lactating women; 8. Known HIV infected persons or drug addicts; 9. Bacterial infection of the knee cavity or suppurative arthritis; 10. Serious primary diseases such as tissue metabolic disorders, immune dysfunction disorders, hematopoietic system and endocrine system or mental diseases, such as coagulation disorders, serious diabetes and drug abuse; 11. Patients with poor compliance, such as unwillingness or inability to limit activities and follow doctor's orders, and inability to follow up on time; 12. Participate in another clinical study within 6 months; 13. have a medical condition that the investigator considers may affect their participation in this study, such as mental disorder, alcohol or drug addiction, malignant or serious illness, etc.; 14. The subject has severe neurological or musculoskeletal disorders, such as myasthenia gravis, muscular atrophy, cerebral infarction, cerebral palsy, etc.; 15. The subject is unable to express, read, express and understand the content of the study protocol, and cannot provide fee dback in appropriate language; 16.The subject has other diseases and life expectancy is less than 2 years; 17. The subject is participating in other clinical trials and has not reached the endpoint. (18) Other patients that the investigator considers unsuitable for this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRI; | — |
Countries
China
Contacts
Public ContactTan Hongbo
The 920th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army
Outcome results
None listed